High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

BACKGROUND: Recent studies have identified myocyte enhancer factor 2C (MEF2C) as cooperating oncogene in acute myeloid leukemia (AML) and suggested a contribution to the aggressive nature of at least some subtypes of AML, raising the possibility that MEF2C could serve as marker of poor-risk AML and,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Laszlo, George S., Alonzo, Todd A., Gudgeon, Chelsea J., Harrington, Kimberly H., Kentsis, Alex, Gerbing, Robert B., Wang, Yi-Cheng, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Walter, Roland B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618184/
https://ncbi.nlm.nih.gov/pubmed/26487643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0215-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller